The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Community-based Neuroendocrine Tumor (NET) Research Study
Official Title: Prospective Observational Study in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated With Lanreotide Depot in a US Community Oncology Setting
Study ID: NCT02730104
Brief Summary: The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot. This is an observational study therefore all data collected will be in accordance with the routine practice of physicians.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Arizona Oncology Associates, Sedona, Arizona, United States
Rocky Mountain Cancer Centers, Denver, Colorado, United States
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
Oncology Hematology Care, Inc., Cincinnati, Ohio, United States
Texas Oncology - Beaumont, Mamie McFaddin Ward Cancer Center, Beaumont, Texas, United States
Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Texas Oncology - Denton South, Denton, Texas, United States
Texas Oncology, Houston, Texas, United States
Texas Oncology-Tyler, Tyler, Texas, United States
Texas Oncology - Deke Slayton Cancer Center, Webster, Texas, United States
Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States
Name: Ipsen Medical Director
Affiliation: Ipsen
Role: STUDY_DIRECTOR